{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:47:59Z","timestamp":1793717279183,"version":"4.6.1"},"reference-count":216,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":2346,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This document provides evidence-based clinical practice guidelines on the management of adult patients with community-acquired pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multidisciplinary panel conducted pragmatic systematic reviews of the relevant research and applied Grading of Recommendations, Assessment, Development, and Evaluation methodology for clinical recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The panel addressed 16 specific areas for recommendations spanning questions of diagnostic testing, determination of site of care, selection of initial empiric antibiotic therapy, and subsequent management decisions. Although some recommendations remain unchanged from the 2007 guideline, the availability of results from new therapeutic trials and epidemiological investigations led to revised recommendations for empiric treatment strategies and additional management decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The panel formulated and provided the rationale for recommendations on selected diagnostic and treatment strategies for adult patients with community-acquired pneumonia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1164\/rccm.201908-1581st","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T10:33:21Z","timestamp":1569926001000},"page":"e45-e67","source":"Crossref","is-referenced-by-count":3302,"title":["Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America"],"prefix":"10.1093","volume":"200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2259-6282","authenticated-orcid":false,"given":"Joshua P.","family":"Metlay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-8018","authenticated-orcid":false,"given":"Grant W.","family":"Waterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7007-588X","authenticated-orcid":false,"given":"Antonio","family":"Anzueto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3122-0773","authenticated-orcid":false,"given":"Jan","family":"Brozek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9702-0371","authenticated-orcid":false,"given":"Kristina","family":"Crothers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-3442","authenticated-orcid":false,"given":"Laura A.","family":"Cooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1996-0533","authenticated-orcid":false,"given":"Nathan C.","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3470-9846","authenticated-orcid":false,"given":"Michael J.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8634-4909","authenticated-orcid":false,"given":"Scott A.","family":"Flanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7114-7614","authenticated-orcid":false,"given":"Marie R.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1968-1400","authenticated-orcid":false,"given":"Mark L.","family":"Metersky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-066X","authenticated-orcid":false,"given":"Daniel M.","family":"Musher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9107-3405","authenticated-orcid":false,"given":"Marcos I.","family":"Restrepo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1056-3216","authenticated-orcid":false,"given":"Cynthia G.","family":"Whitney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"2026030321360974500_bib1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jclinepi.2010.09.012","article-title":"GRADE guidelines: 2. Framing the question and deciding on important outcomes","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2026030321360974500_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1001\/jama.1997.03550170070035","article-title":"Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination","volume":"278","author":"Metlay","year":"1997","journal-title":"JAMA"},{"key":"2026030321360974500_bib4","first-page":"558","article-title":"Usefulness of sputum Gram staining in community-acquired pneumonia [in Japanese]","volume-title":"Nihon Kokyuki Gakkai Zasshi","author":"Sato","year":"2002"},{"key":"2026030321360974500_bib5","first-page":"792","article-title":"Does sputum culture affect the management and\/or outcome of community-acquired pneumonia?","volume-title":"East Mediterr Health J","author":"Shariatzadeh","year":"2009"},{"key":"2026030321360974500_bib6","first-page":"152","article-title":"Sputum examination in the clinical management of community-acquired pneumonia [in Portuguese]","volume-title":"J Bras Pneumol","author":"Signori","year":"2008"},{"key":"2026030321360974500_bib7","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/intqhc\/mzt078","article-title":"Impact of guideline-concordant microbiological testing on outcomes of pneumonia","volume":"26","author":"Uematsu","year":"2014","journal-title":"Int J Qual Health Care"},{"key":"2026030321360974500_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/0036554021000026967","article-title":"Limited value of routine microbiological diagnostics in patients hospitalized for community-acquired pneumonia","volume":"34","author":"Lidman","year":"2002","journal-title":"Scand J Infect Dis"},{"key":"2026030321360974500_bib9","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1164\/ajrccm.160.1.9806048","article-title":"Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia","volume":"160","author":"Sanyal","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib10","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1136\/thx.2004.030411","article-title":"Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study","volume":"60","author":"van der Eerden","year":"2005","journal-title":"Thorax"},{"key":"2026030321360974500_bib11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1183\/09031936.02.01942001","article-title":"Factors associated with unknown aetiology in patients with community-acquired pneumonia","volume":"20","author":"Ewig","year":"2002","journal-title":"Eur Respir J"},{"key":"2026030321360974500_bib12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1378\/chest.121.5.1486","article-title":"Applying sputum as a diagnostic tool in pneumonia: limited yield, minimal impact on treatment decisions","volume":"121","author":"Ewig","year":"2002","journal-title":"Chest"},{"key":"2026030321360974500_bib13","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1001\/archinte.164.16.1807","article-title":"Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system","volume":"164","author":"Garc\u00eda-V\u00e1zquez","year":"2004","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1378\/chest.93.1.43","article-title":"Community-acquired pneumonia: importance of initial noninvasive bacteriologic and radiographic investigations","volume":"93","author":"L\u00e9vy","year":"1988","journal-title":"Chest"},{"key":"2026030321360974500_bib15","first-page":"CR171","article-title":"Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization","volume":"14","author":"Miyashita","year":"2008","journal-title":"Med Sci Monit"},{"key":"2026030321360974500_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/318151","article-title":"Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization","volume":"31","author":"Ros\u00f3n","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib17","first-page":"241","article-title":"Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia","volume-title":"Eur J Clin Microbiol Infect Dis","author":"van der Eerden","year":"2005"},{"key":"2026030321360974500_bib18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1086\/421497","article-title":"Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia","volume":"39","author":"Musher","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib19","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1513\/AnnalsATS.201506-368BC","article-title":"Use of tracheal aspirate culture in newly intubated patients with community-onset pneumonia","volume":"13","author":"McCauley","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"2026030321360974500_bib20","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1001\/jama.1997.03550230056037","article-title":"Quality of care, process, and outcomes in elderly patients with pneumonia","volume":"278","author":"Meehan","year":"1997","journal-title":"JAMA"},{"key":"2026030321360974500_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jemermed.2006.12.034","article-title":"Selective use of blood cultures in emergency department pneumonia patients","volume":"33","author":"Benenson","year":"2007","journal-title":"J Emerg Med"},{"key":"2026030321360974500_bib22","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/archinte.161.17.2099","article-title":"Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals","volume":"161","author":"Dedier","year":"2001","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1378\/chest.123.4.1142","article-title":"The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study","volume":"123","author":"Campbell","year":"2003","journal-title":"Chest"},{"key":"2026030321360974500_bib24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/rmed.2000.0977","article-title":"The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures","volume":"95","author":"Waterer","year":"2001","journal-title":"Respir Med"},{"key":"2026030321360974500_bib25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1378\/chest.116.5.1278","article-title":"The impact of blood cultures on antibiotic therapy in pneumococcal pneumonia","volume":"116","author":"Waterer","year":"1999","journal-title":"Chest"},{"key":"2026030321360974500_bib26","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.200309-1248OC","article-title":"Predicting bacteremia in patients with community-acquired pneumonia","volume":"169","author":"Metersky","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib27","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s11739-016-1445-3","article-title":"Adherence to guidelines for hospitalized community-acquired pneumonia over time and its impact on health outcomes and mortality","volume":"11","author":"Costantini","year":"2016","journal-title":"Intern Emerg Med"},{"key":"2026030321360974500_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/thx.2009.118588","article-title":"Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia","volume":"65","author":"Falguera","year":"2010","journal-title":"Thorax"},{"key":"2026030321360974500_bib29","doi-asserted-by":"crossref","first-page":"w13679","DOI":"10.4414\/smw.2012.13679","article-title":"The routine use of urinary pneumococcal antigen test in hospitalised patients with community acquired pneumonia has limited impact for adjustment of antibiotic treatment","volume":"142","author":"Piso","year":"2012","journal-title":"Swiss Med Wkly"},{"key":"2026030321360974500_bib30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.15585\/mmwr.mm6522e1","article-title":"Vital signs: deficiencies in environmental control identified in outbreaks of legionnaires\u2019 disease. North America, 2000-2014","volume":"65","author":"Garrison","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026030321360974500_bib31","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.15585\/mmwr.mm6442a2","article-title":"Active bacterial core surveillance for legionellosis: United States, 2011-2013","volume":"64","author":"Dooling","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026030321360974500_bib32","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMp1400034","article-title":"Preventing and controlling influenza with available interventions","volume":"370","author":"Uyeki","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321360974500_bib33","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa","volume":"68","author":"Uyeki","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib34","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMra1312885","article-title":"Community-acquired pneumonia","volume":"371","author":"Musher","year":"2014","journal-title":"N Engl J Med"},{"key":"2026030321360974500_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1164\/rccm.200512-1922OC","article-title":"Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial","volume":"174","author":"Christ-Crain","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"2026030321360974500_bib36","first-page":"CD007498","article-title":"Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections","author":"Schuetz","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030321360974500_bib37","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cid\/cix317","article-title":"Procalcitonin as a marker of etiology in adults hospitalized with community-acquired pneumonia","volume":"65","author":"Self","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib38","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(18)30215-9","article-title":"Low procalcitonin, community acquired pneumonia, and antibiotic therapy","volume":"18","author":"Kamat","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2026030321360974500_bib39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJM199701233360402","article-title":"A prediction rule to identify low-risk patients with community-acquired pneumonia","volume":"336","author":"Fine","year":"1997","journal-title":"N Engl J Med"},{"key":"2026030321360974500_bib40","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/thorax.58.5.377","article-title":"Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study","volume":"58","author":"Lim","year":"2003","journal-title":"Thorax"},{"key":"2026030321360974500_bib41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amjmed.2005.01.006","article-title":"Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia","volume":"118","author":"Aujesky","year":"2005","journal-title":"Am J Med"},{"key":"2026030321360974500_bib42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jama.283.6.749","article-title":"A controlled trial of a critical pathway for treatment of community-acquired pneumonia","volume":"283","author":"Marrie","year":"2000","journal-title":"JAMA"},{"key":"2026030321360974500_bib43","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7326\/0003-4819-143-12-200512200-00006","article-title":"Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial","volume":"143","author":"Yealy","year":"2005","journal-title":"Ann Intern Med"},{"key":"2026030321360974500_bib44","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-142-3-200502010-00006","article-title":"Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients","volume":"142","author":"Carratal\u00e0","year":"2005","journal-title":"Ann Intern Med"},{"key":"2026030321360974500_bib45","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/archinte.158.12.1350","article-title":"Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial","volume":"158","author":"Atlas","year":"1998","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jemermed.2010.04.018","article-title":"The effects of incorporating a pneumonia severity index into the admission protocol for community-acquired pneumonia","volume":"42","author":"Jo","year":"2012","journal-title":"J Emerg Med"},{"key":"2026030321360974500_bib47","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.arbres.2012.12.008","article-title":"Improved management of community-acquired pneumonia in the emergency department","volume":"49","author":"Juli\u00e1n-Jim\u00e9nez","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"2026030321360974500_bib48","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1086\/509331","article-title":"Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study","volume":"44","author":"Renaud","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib49","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1525-1497.2006.00510.x","article-title":"Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial","volume":"21","author":"Labarere","year":"2006","journal-title":"J Gen Intern Med"},{"key":"2026030321360974500_bib50","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.amjmed.2005.06.035","article-title":"Low-risk patients admitted with community-acquired pneumonia","volume":"118","author":"Marrie","year":"2005","journal-title":"Am J Med"},{"key":"2026030321360974500_bib51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.annemergmed.2015.02.003","article-title":"Impact of an electronic clinical decision support tool for emergency department patients with pneumonia","volume":"66","author":"Dean","year":"2015","journal-title":"Ann Emerg Med"},{"key":"2026030321360974500_bib52","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5694\/j.1326-5377.2005.tb07026.x","article-title":"Home management of mild to moderately severe community-acquired pneumonia: a randomised controlled trial","volume":"183","author":"Richards","year":"2005","journal-title":"Med J Aust"},{"key":"2026030321360974500_bib53","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1378\/chest.125.6.2140","article-title":"Treatment costs of community-acquired pneumonia in an employed population","volume":"125","author":"Colice","year":"2004","journal-title":"Chest"},{"key":"2026030321360974500_bib54","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1111\/j.1532-5415.2012.04208.x","article-title":"Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population","volume":"60","author":"Yu","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"2026030321360974500_bib55"},{"key":"2026030321360974500_bib56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1378\/chest.10-1296","article-title":"CURB-65 pneumonia severity assessment adapted for electronic decision support","volume":"140","author":"Jones","year":"2011","journal-title":"Chest"},{"key":"2026030321360974500_bib57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/596307","article-title":"Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America\/American Thoracic Society guidelines to predict an intensive care unit admission","volume":"48","author":"Liapikou","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib58","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/thx.2009.113795","article-title":"Validation and clinical implications of the IDSA\/ATS minor criteria for severe community-acquired pneumonia","volume":"64","author":"Phua","year":"2009","journal-title":"Thorax"},{"key":"2026030321360974500_bib59","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1093\/cid\/cir463","article-title":"Validation of the Infectious Diseases Society of America\/American Thoracic Society minor criteria for intensive care unit admission in community-acquired pneumonia patients without major criteria or contraindications to intensive care unit care","volume":"53","author":"Chalmers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1086\/589754","article-title":"SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia","volume":"47","author":"Charles","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib61","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1097\/CCM.0b013e3181b030d9","article-title":"Validation of the Infectious Disease Society of America\/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia","volume":"37","author":"Brown","year":"2009","journal-title":"Crit Care Med"},{"key":"2026030321360974500_bib62","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/cc11447","article-title":"Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis","volume":"16","author":"Marti","year":"2012","journal-title":"Crit Care"},{"key":"2026030321360974500_bib63","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00134-011-2261-x","article-title":"Severity assessment tools to guide ICU admission in community-acquired pneumonia: systematic review and meta-analysis","volume":"37","author":"Chalmers","year":"2011","journal-title":"Intensive Care Med"},{"key":"2026030321360974500_bib64","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1440-1843.2012.02225.x","article-title":"Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia","volume":"17","author":"Brown","year":"2012","journal-title":"Respirology"},{"key":"2026030321360974500_bib65","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1183\/09031936.00154209","article-title":"The impact of a delay in intensive care unit admission for community-acquired pneumonia","volume":"36","author":"Phua","year":"2010","journal-title":"Eur Respir J"},{"key":"2026030321360974500_bib66","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1553-2712.2012.01301.x","article-title":"Outcomes of early, late, and no admission to the intensive care unit for patients hospitalized with community-acquired pneumonia","volume":"19","author":"Renaud","year":"2012","journal-title":"Acad Emerg Med"},{"key":"2026030321360974500_bib67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1378\/chest.09-1547","article-title":"Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality","volume":"137","author":"Restrepo","year":"2010","journal-title":"Chest"},{"key":"2026030321360974500_bib68","article-title":"Antibiotics for community-acquired pneumonia in adolescent and adult outpatients","author":"Pakhale","year":"2014"},{"key":"2026030321360974500_bib69","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1128\/AAC.05596-11","article-title":"Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies","volume":"56","author":"English","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib70","first-page":"748","article-title":"Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia","volume":"16","author":"Fogarty","year":"1999","journal-title":"Infect Med"},{"key":"2026030321360974500_bib71","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0149-2918(02)80084-4","article-title":"A comparison of cefditoren pivoxil and amoxicillin\/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study","volume":"24","author":"Fogarty","year":"2002","journal-title":"Clin Ther"},{"key":"2026030321360974500_bib72","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clin Ther"},{"key":"2026030321360974500_bib73","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/37.3.555","article-title":"Comparison of oral cefuroxime axetil and oral amoxycillin\/clavulanate in the treatment of community-acquired pneumonia","volume":"37","author":"Higuera","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib74","first-page":"255","article-title":"Clinical evaluation of telithromycin for community-acquired pneumonia phase III double-blind comparative study of telithromycin versus levofloxacin","volume":"51","author":"Kohno","year":"2003","journal-title":"Japanese Journal of Chemotherapy"},{"key":"2026030321360974500_bib75","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jmii.2015.09.005","article-title":"A randomized, double-blind, multicenter phase II study comparing the efficacy and safety of oral nemonoxacin with oral levofloxacin in the treatment of community-acquired pneumonia","volume":"50","author":"Liu","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"key":"2026030321360974500_bib76","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00044011-200323080-00001","article-title":"Comparison of clarithromycin and amoxicillin\/clavulanic acid for community-acquired pneumonia in an era of drug-resistant Streptococcus pneumoniae","volume":"23","author":"Bonvehi","year":"2003","journal-title":"Clin Drug Investig"},{"key":"2026030321360974500_bib77","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults","volume":"49","author":"D\u2019Ignazio","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib78","first-page":"75","article-title":"Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia","volume-title":"J Antimicrob Chemother","author":"Salvarezza","year":"1998"},{"key":"2026030321360974500_bib79","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib80","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.00295-10","article-title":"Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia","volume":"54","author":"van Rensburg","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib81","first-page":"1014","article-title":"Twice daily dosing of erythromycin acistrate in the treatment of acute bronchitis and pneumonia","volume":"43","author":"Wiesner","year":"1993","journal-title":"Arzneimittelforschung"},{"key":"2026030321360974500_bib82","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers Dunbar","year":"2004","journal-title":"Clin Ther"},{"key":"2026030321360974500_bib83","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","article-title":"Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","volume":"57","author":"Oldach","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib84","first-page":"413","article-title":"Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime","volume-title":"Respiration","author":"Rovira","year":"1999"},{"key":"2026030321360974500_bib85","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1183\/09031936.00109007","article-title":"Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis","volume":"31","author":"Maimon","year":"2008","journal-title":"Eur Respir J"},{"key":"2026030321360974500_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.119.1.185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults","volume":"119","author":"Petitpretz","year":"2001","journal-title":"Chest"},{"key":"2026030321360974500_bib87","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1086\/516366","article-title":"Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults","volume":"26","author":"Aubier","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib88","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"2026030321360974500_bib89","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jac\/dki480","article-title":"Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin\/clavulanate (2000\/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae","volume":"57","author":"Siquier","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib90","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1179\/joc.2008.20.1.77","article-title":"Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875\/125 mg twice daily for 7 days","volume":"20","author":"Paris","year":"2008","journal-title":"J Chemother"},{"key":"2026030321360974500_bib91","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2710.2009.01073.x","article-title":"Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia","volume":"35","author":"Mokabberi","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"2026030321360974500_bib92","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1001\/archinte.159.3.266","article-title":"Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia","volume":"159","author":"Ailani","year":"1999","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib93","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/341978","article-title":"Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae","volume":"35","author":"Lonks","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib94","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1086\/505871","article-title":"Macrolide resistance in bacteremic pneumococcal disease: implications for patient management","volume":"43","author":"Daneman","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib95","author":"Centers for Disease Control and Prevention"},{"key":"2026030321360974500_bib96","author":"U.S. Food and Drug Administration"},{"key":"2026030321360974500_bib97","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/378406","article-title":"Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib98","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0149-2918(02)80034-0","article-title":"A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia","volume":"24","author":"Frank","year":"2002","journal-title":"Clin Ther"},{"key":"2026030321360974500_bib99","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03261911","article-title":"High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study","volume":"32","author":"Lee","year":"2012","journal-title":"Clin Drug Investig"},{"key":"2026030321360974500_bib100","first-page":"321","article-title":"An open-label, randomized comparison of levofloxacin and amoxicillin\/clavulanate plus clarithromycin for the treatment of hospitalized patients with community-acquired pneumonia","volume":"30","author":"Lin","year":"2007","journal-title":"Chang Gung Med J"},{"key":"2026030321360974500_bib101","first-page":"367","article-title":"Moxifloxacin monotherapy compared to amoxicillin-clavulanate plus roxithromycin for nonsevere community-acquired pneumonia in adults with risk factors","volume-title":"Eur J Clin Microbiol Infect Dis","author":"Portier","year":"2005"},{"key":"2026030321360974500_bib102","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1056\/NEJMoa1406330","article-title":"Antibiotic treatment strategies for community-acquired pneumonia in adults","volume":"372","author":"Postma","year":"2015","journal-title":"N Engl J Med"},{"key":"2026030321360974500_bib103","first-page":"421","article-title":"Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia","volume-title":"J Huazhong Univ Sci Technolog Med Sci","author":"Xu","year":"2006"},{"key":"2026030321360974500_bib104","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2015.04.010","article-title":"Fluoroquinolones or macrolides alone versus combined with \u03b2-lactams for adults with community-acquired pneumonia: systematic review and meta-analysis","volume":"46","author":"Raz-Pasteur","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2026030321360974500_bib105","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.2016.0115","article-title":"Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review","volume":"315","author":"Lee","year":"2016","journal-title":"JAMA"},{"key":"2026030321360974500_bib106","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJMoa1800201","article-title":"Omadacycline for community-acquired bacterial pneumonia","volume":"380","author":"Stets","year":"2019","journal-title":"N Engl J Med"},{"key":"2026030321360974500_bib107","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1001\/jamainternmed.2014.4887","article-title":"\u03b2-Lactam monotherapy vs \u03b2-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial","volume":"174","author":"Garin","year":"2014","journal-title":"JAMA Intern Med"},{"key":"2026030321360974500_bib108","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/jac\/dku033","article-title":"\u03b2-Lactam\/macrolide dual therapy versus \u03b2-lactam monotherapy for the treatment of community-acquired pneumonia in adults: a systematic review and meta-analysis","volume":"69","author":"Nie","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib109","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/resp.12835","article-title":"Beta-lactam plus macrolides or beta-lactam alone for community-acquired pneumonia: a systematic review and meta-analysis","volume":"21","author":"Horita","year":"2016","journal-title":"Respirology"},{"key":"2026030321360974500_bib110","article-title":"Efficacy and safety of iv-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial","author":"File","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib111","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CCM.0b013e3182a66b9b","article-title":"Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis","volume":"42","author":"Sligl","year":"2014","journal-title":"Crit Care Med"},{"key":"2026030321360974500_bib112","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cmi.2016.12.002","article-title":"Fluoroquinolones or macrolides in combination with \u03b2-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis","volume":"23","author":"Vardakas","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2026030321360974500_bib113","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1378\/chest.111.5.1266","article-title":"Quantitative aspiration during sleep in normal subjects","volume":"111","author":"Gleeson","year":"1997","journal-title":"Chest"},{"key":"2026030321360974500_bib114","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1056\/NEJM200103013440908","article-title":"Aspiration pneumonitis and aspiration pneumonia","volume":"344","author":"Marik","year":"2001","journal-title":"N Engl J Med"},{"key":"2026030321360974500_bib115","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1532-5415.1986.tb04300.x","article-title":"Nursing home-acquired pneumonia: a case-control study","volume":"34","author":"Marrie","year":"1986","journal-title":"J Am Geriatr Soc"},{"key":"2026030321360974500_bib116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11739-012-0764-2","article-title":"A comparison between time to clinical stability in community-acquired aspiration pneumonia and community-acquired pneumonia","volume":"9","author":"Jaoude","year":"2014","journal-title":"Intern Emerg Med"},{"key":"2026030321360974500_bib117","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.1975.03260220039016","article-title":"Treatment of aspiration pneumonia and primary lung abscess: penicillin G vs clindamycin","volume":"234","author":"Bartlett","year":"1975","journal-title":"JAMA"},{"key":"2026030321360974500_bib118","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/archinte.1975.00330050085014","article-title":"Bacteriologic flora of aspiration-induced pulmonary infections","volume":"135","author":"Cesar","year":"1975","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib119","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1164\/rccm.200212-1543OC","article-title":"Microbiology of severe aspiration pneumonia in institutionalized elderly","volume":"167","author":"El-Solh","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1378\/chest.115.1.178","article-title":"The role of anaerobes in patients with ventilator-associated pneumonia and aspiration pneumonia: a prospective study","volume":"115","author":"Marik","year":"1999","journal-title":"Chest"},{"key":"2026030321360974500_bib121","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF01690548","article-title":"Is penicillin G an adequate initial treatment for aspiration pneumonia? A prospective evaluation using a protected specimen brush and quantitative cultures","volume":"19","author":"Mier","year":"1993","journal-title":"Intensive Care Med"},{"key":"2026030321360974500_bib122","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200405-644ST","article-title":"Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia","volume":"171","author":"American Thoracic Society","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib123","doi-asserted-by":"crossref","first-page":"3854","DOI":"10.1378\/chest.128.6.3854","article-title":"Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia","volume":"128","author":"Kollef","year":"2005","journal-title":"Chest"},{"key":"2026030321360974500_bib124","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcrc.2016.08.004","article-title":"Health care-associated pneumonia in the intensive care unit: guideline-concordant antibiotics and outcomes","volume":"36","author":"Attridge","year":"2016","journal-title":"J Crit Care"},{"key":"2026030321360974500_bib125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1183\/09031936.00141110","article-title":"Guideline-concordant therapy and outcomes in healthcare-associated pneumonia","volume":"38","author":"Attridge","year":"2011","journal-title":"Eur Respir J"},{"key":"2026030321360974500_bib126","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/cid\/cit734","article-title":"Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis","volume":"58","author":"Chalmers","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib127","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1345\/aph.1R322","article-title":"Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home","volume":"47","author":"Chen","year":"2013","journal-title":"Ann Pharmacother"},{"key":"2026030321360974500_bib128","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/resp.12132","article-title":"Healthcare-associated pneumonia: a US disease or relevant to the Asia Pacific, too?","volume":"18","author":"Dobler","year":"2013","journal-title":"Respirology"},{"key":"2026030321360974500_bib129","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.rmed.2012.07.002","article-title":"Adding fuel to the flames? It is time to leave HCAP","volume":"106","author":"Ewig","year":"2012","journal-title":"Respir Med"},{"key":"2026030321360974500_bib130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/jac\/dkr176","article-title":"Impact of guideline-consistent therapy on outcome of patients with healthcare-associated and community-acquired pneumonia","volume":"66","author":"Grenier","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib131","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/cid\/civ629","article-title":"Trends in antibiotic use and nosocomial pathogens in hospitalized Veterans with pneumonia at 128 medical centers, 2006-2010","volume":"61","author":"Jones","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib132","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.jiac.2015.05.002","article-title":"Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia","volume":"21","author":"Kamata","year":"2015","journal-title":"J Infect Chemother"},{"key":"2026030321360974500_bib133","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/jac\/dku533","article-title":"Association of guideline-based antimicrobial therapy and outcomes in healthcare-associated pneumonia","volume":"70","author":"Rothberg","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib134","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rmed.2014.10.017","article-title":"Predicting risk of drug-resistant organisms in pneumonia: moving beyond the HCAP model","volume":"109","author":"Webb","year":"2015","journal-title":"Respir Med"},{"key":"2026030321360974500_bib135","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1128\/AAC.03071-15","article-title":"Derivation and multicenter validation of the drug resistance in pneumonia clinical prediction score","volume":"60","author":"Webb","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib136","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1001\/archinte.162.16.1849","article-title":"Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis","volume":"162","author":"Arancibia","year":"2002","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib137","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.chest.2016.03.042","article-title":"Community-acquired pneumonia due to multidrug- and non-multidrug-resistant Pseudomonas aeruginosa","volume":"150","author":"Cill\u00f3niz","year":"2016","journal-title":"Chest"},{"key":"2026030321360974500_bib138","doi-asserted-by":"crossref","first-page":"e0119528","DOI":"10.1371\/journal.pone.0119528","article-title":"Individualizing risk of multidrug-resistant pathogens in community-onset pneumonia","volume":"10","author":"Falcone","year":"2015","journal-title":"PLoS One"},{"key":"2026030321360974500_bib139","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1128\/AAC.02582-14","article-title":"Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia","volume":"58","author":"Gross","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2334-11-61","article-title":"Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital","volume":"11","author":"Jung","year":"2011","journal-title":"BMC Infect Dis"},{"key":"2026030321360974500_bib141","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1471-2334-13-370","article-title":"Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia","volume":"13","author":"Jung","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2026030321360974500_bib142","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/resp.12651","article-title":"Predictors of Pseudomonas and methicillin-resistant Staphylococcus aureus in hospitalized patients with healthcare-associated pneumonia","volume":"21","author":"Metersky","year":"2016","journal-title":"Respirology"},{"key":"2026030321360974500_bib143","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2334-14-252","article-title":"Patients presenting to the hospital with MRSA pneumonia: differentiating characteristics and outcomes with empiric treatment","volume":"14","author":"Minejima","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2026030321360974500_bib144","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/j.rmed.2007.05.011","article-title":"Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease","volume":"101","author":"Pifarre","year":"2007","journal-title":"Respir Med"},{"key":"2026030321360974500_bib145","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jinf.2015.03.009","article-title":"Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients","volume":"71","author":"Polverino","year":"2015","journal-title":"J Infect"},{"key":"2026030321360974500_bib146","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1513\/AnnalsATS.201407-305OC","article-title":"Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia","volume":"12","author":"Prina","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2026030321360974500_bib147","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/resp.13115","article-title":"The respiratory threat posed by multidrug resistant Gram-negative bacteria","volume":"22","author":"Rodrigo-Troyano","year":"2017","journal-title":"Respirology"},{"key":"2026030321360974500_bib148","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.201301-0079OC","article-title":"Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia","volume":"188","author":"Shindo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib149","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/1471-2334-13-268","article-title":"A risk score for identifying methicillin-resistant Staphylococcus aureus in patients presenting to the hospital with pneumonia","volume":"13","author":"Shorr","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2026030321360974500_bib150","first-page":"51","article-title":"Clinical predictors of methicillin-resistant Staphylococcus aureus in nosocomial and healthcare-associated pneumonia: a multicenter, matched case-control study","volume-title":"Eur J Clin Microbiol Infect Dis","author":"Torre-Cisneros","year":"2018"},{"key":"2026030321360974500_bib151","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1183\/09031936.00091809","article-title":"Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors","volume":"35","author":"von Baum","year":"2010","journal-title":"Eur Respir J"},{"key":"2026030321360974500_bib152","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jfma.2015.03.009","article-title":"Selection of empirical antibiotics for health care-associated pneumonia via integration of pneumonia severity index and risk factors of drug-resistant pathogens","volume":"115","author":"Wang","year":"2016","journal-title":"J Formos Med Assoc"},{"key":"2026030321360974500_bib153","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.rmed.2013.05.006","article-title":"Risk factors for methicillin-resistant Staphylococcus aureus in patients with community-onset and hospital-onset pneumonia","volume":"107","author":"Wooten","year":"2013","journal-title":"Respir Med"},{"key":"2026030321360974500_bib154","doi-asserted-by":"crossref","first-page":"4706150","DOI":"10.1155\/2016\/4706150","article-title":"Liver cirrhosis and diabetes mellitus are risk factors for Staphylococcus aureus infection in patients with healthcare-associated or hospital-acquired pneumonia","volume":"2016","author":"Wu","year":"2016","journal-title":"Pulm Med"},{"key":"2026030321360974500_bib155","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/S1473-3099(16)30267-5","article-title":"Global initiative for methicillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study","volume":"16","author":"Aliberti","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2026030321360974500_bib156","doi-asserted-by":"crossref","first-page":"1701190","DOI":"10.1183\/13993003.01190-2017","article-title":"Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients","volume":"52","author":"Restrepo","year":"2018","journal-title":"Eur Respir J"},{"key":"2026030321360974500_bib157","first-page":"936, e11-8","article-title":"De-escalation therapy among bacteraemic patients with community-acquired pneumonia","volume-title":"Clin Microbiol Infect","author":"Carugati","year":"2015"},{"key":"2026030321360974500_bib158","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jac\/dkw441","article-title":"Impact of antibiotic de-escalation on clinical outcomes in community-acquired pneumococcal pneumonia","volume":"72","author":"Viasus","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib159","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/jac\/dku109","article-title":"Effect of antibiotic streamlining on patient outcome in pneumococcal bacteraemia","volume":"69","author":"Cremers","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026030321360974500_bib160","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jinf.2016.07.001","article-title":"De-escalation versus continuation of empirical antimicrobial therapy in community-acquired pneumonia","volume":"73","author":"Yamana","year":"2016","journal-title":"J Infect"},{"key":"2026030321360974500_bib161","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1513\/AnnalsATS.201606-486BC","article-title":"Broad- versus narrow-spectrum oral antibiotic transition and outcomes in health care-associated pneumonia","volume":"14","author":"Buckel","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026030321360974500_bib162","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc9373","article-title":"De-escalation as part of a global strategy of empiric antibiotherapy management: a retrospective study in a medico-surgical intensive care unit","volume":"14","author":"Morel","year":"2010","journal-title":"Crit Care"},{"key":"2026030321360974500_bib163","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00134-014-3411-8","article-title":"De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial","volume":"40","author":"Leone","year":"2014","journal-title":"Intensive Care Med"},{"key":"2026030321360974500_bib164","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/17512433.2017.1293520","article-title":"Collaborative approach of individual participant data of prospective studies of de-escalation in non-immunosuppressed critically ill patients with sepsis","volume":"10","author":"Guti\u00e9rrez-Pizarraya","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2026030321360974500_bib165","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1017\/ice.2017.98","article-title":"Variation in empiric coverage versus detection of methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa in hospitalizations for community-onset pneumonia across 128 US Veterans Affairs Medical Centers","volume":"38","author":"Jones","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026030321360974500_bib166","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib167","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1128\/AAC.01805-13","article-title":"Predictive value of methicillin-resistant Staphylococcus aureus (MRSA) nasal swab PCR assay for MRSA pneumonia","volume":"58","author":"Dangerfield","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciy024","article-title":"The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications","volume":"67","author":"Parente","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib169","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","article-title":"Surviving sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016","volume":"43","author":"Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"2026030321360974500_bib170","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1164\/rccm.200406-808OC","article-title":"Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study","volume":"171","author":"Confalonieri","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib171","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejcdt.2013.03.009","article-title":"Adjuvant role of corticosteroids in the treatment of community-acquired pneumonia","volume":"62","author":"Nafae","year":"2013","journal-title":"Egypt J Chest Dis Tuberc"},{"key":"2026030321360974500_bib172","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(14)62447-8","article-title":"Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"385","author":"Blum","year":"2015","journal-title":"Lancet"},{"key":"2026030321360974500_bib173","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.2015.88","article-title":"Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial","volume":"313","author":"Torres","year":"2015","journal-title":"JAMA"},{"key":"2026030321360974500_bib174","doi-asserted-by":"crossref","first-page":"14061","DOI":"10.1038\/srep14061","article-title":"Adjunctive systemic corticosteroids for hospitalized community-acquired pneumonia: systematic review and meta-analysis 2015 update","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"key":"2026030321360974500_bib175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7326\/M15-0715","article-title":"Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis","volume":"163","author":"Siemieniuk","year":"2015","journal-title":"Ann Intern Med"},{"key":"2026030321360974500_bib176","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/cid\/cix801","article-title":"Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data metaanalysis","volume":"66","author":"Briel","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib177","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5847\/wjem.j.1920-8642.2015.03.002","article-title":"Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia: a meta-analysis of randomized controlled trials","volume":"6","author":"Chen","year":"2015","journal-title":"World J Emerg Med"},{"key":"2026030321360974500_bib178","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.2016.14799","article-title":"Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial","volume":"316","author":"Keh","year":"2016","journal-title":"JAMA"},{"key":"2026030321360974500_bib179","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"2026030321360974500_bib180","first-page":"CD010406","article-title":"Corticosteroids as adjunctive therapy in the treatment of influenza","volume":"3","author":"Rodrigo","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2026030321360974500_bib181","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/thx.2009.130799","article-title":"Outcomes of adults hospitalised with severe influenza","volume":"65","author":"Lee","year":"2010","journal-title":"Thorax"},{"key":"2026030321360974500_bib182","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/523584","article-title":"Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada","volume":"45","author":"McGeer","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib183","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1086\/652446","article-title":"Fatalities associated with the 2009 H1N1 influenza A virus in New York city","volume":"50","author":"Lee","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib184","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1001\/jama.2010.479","article-title":"Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States","volume":"303","author":"Siston","year":"2010","journal-title":"JAMA"},{"key":"2026030321360974500_bib185","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/cid\/cis636","article-title":"Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09","volume":"55","author":"Louie","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib186","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"key":"2026030321360974500_bib187","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/cix127","article-title":"Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis","volume":"64","author":"Venkatesan","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib188","first-page":"e321","article-title":"Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza","volume-title":"Int J Infect Dis","author":"Metersky","year":"2012"},{"key":"2026030321360974500_bib189","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2353\/ajpath.2010.100115","article-title":"2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States","volume":"177","author":"Shieh","year":"2010","journal-title":"Am J Pathol"},{"key":"2026030321360974500_bib190","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3201\/eid1206.051141","article-title":"Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season","volume":"12","author":"Hageman","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2026030321360974500_bib191","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1086\/652291","article-title":"Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza","volume":"50","author":"Jean","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib192","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/infdis\/jir861","article-title":"Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection","volume":"205","author":"Paddock","year":"2012","journal-title":"J Infect Dis"},{"key":"2026030321360974500_bib193","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jinf.2015.11.007","article-title":"Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: a CHAID decision-tree analysis","volume":"72","author":"Rodr\u00edguez","year":"2016","journal-title":"J Infect"},{"key":"2026030321360974500_bib194","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/bmj.332.7554.1355","article-title":"Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study","volume":"332","author":"el Moussaoui","year":"2006","journal-title":"BMJ"},{"key":"2026030321360974500_bib195","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00045391-199907000-00007","article-title":"Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study","volume":"6","author":"Siegel","year":"1999","journal-title":"Am J Ther"},{"key":"2026030321360974500_bib196","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1086\/377539","article-title":"High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm","volume":"37","author":"Dunbar","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib197","first-page":"360","article-title":"Efficacit\u00e9 compar\u00e9e de la ceftriaxone dans un traitement de dix jours versus un traitement raccourci de cinq jours des pneumonies aigues communautaires de l\u2019adulte hospitalis\u00e9 avec facteur de risque [in French]","volume":"32","author":"Leophonte","year":"2992","journal-title":"Med Mal Infect"},{"key":"2026030321360974500_bib198","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.2165\/00003495-200868130-00004","article-title":"Short- versus long-course antibacterial therapy for community-acquired pneumonia: a meta-analysis","volume":"68","author":"Dimopoulos","year":"2008","journal-title":"Drugs"},{"key":"2026030321360974500_bib199","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.amjmed.2007.04.023","article-title":"Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis","volume":"120","author":"Li","year":"2007","journal-title":"Am J Med"},{"key":"2026030321360974500_bib200","doi-asserted-by":"crossref","first-page":"e00635-18","DOI":"10.1128\/AAC.00635-18","article-title":"Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults","volume":"62","author":"Tansarli","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib201","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1465-9921-10-65","article-title":"Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP: results from the German competence network CAPNETZ","volume":"10","author":"Kr\u00fcger","year":"2009","journal-title":"Respir Res"},{"key":"2026030321360974500_bib202","doi-asserted-by":"crossref","first-page":"R44","DOI":"10.1186\/cc13760","article-title":"Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis","volume":"18","author":"Pfister","year":"2014","journal-title":"Crit Care"},{"key":"2026030321360974500_bib203","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/infdis\/jit579","article-title":"Serum procalcitonin level, viral polymerase chain reaction analysis, and lower respiratory tract infection","volume":"209","author":"Musher","year":"2014","journal-title":"J Infect Dis"},{"key":"2026030321360974500_bib204","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1001\/jama.279.18.1452","article-title":"Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines","volume":"279","author":"Halm","year":"1998","journal-title":"JAMA"},{"key":"2026030321360974500_bib205","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1128\/AAC.02632-13","article-title":"Relationship between time to clinical response and outcomes among Pneumonia Outcomes Research Team (PORT) risk class III and IV hospitalized patients with community-acquired pneumonia who received ceftriaxone and azithromycin","volume":"58","author":"Zasowski","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2026030321360974500_bib206","doi-asserted-by":"crossref","first-page":"e0157350","DOI":"10.1371\/journal.pone.0157350","article-title":"Predictors and implications of early clinical stability in patients hospitalized for moderately severe community-acquired pneumonia","volume":"11","author":"Garin","year":"2016","journal-title":"PLoS One"},{"key":"2026030321360974500_bib207","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/thx.2003.017756","article-title":"Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome","volume":"59","author":"Men\u00e9ndez","year":"2004","journal-title":"Thorax"},{"key":"2026030321360974500_bib208","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1086\/426028","article-title":"Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients","volume":"39","author":"Men\u00e9ndez","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026030321360974500_bib209","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1164\/ajrccm.162.1.9907023","article-title":"Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications","volume":"162","author":"Arancibia","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"2026030321360974500_bib210","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamainternmed.2016.3633","article-title":"Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial","volume":"176","author":"Uranga","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2026030321360974500_bib211","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/imj.12699","article-title":"Is post-pneumonia chest X-ray for lung malignancy useful? Results of an audit of current practice","volume":"45","author":"Macdonald","year":"2015","journal-title":"Intern Med J"},{"key":"2026030321360974500_bib212","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/00365549309169676","article-title":"Association of pneumonia and lung cancer: the value of convalescent chest radiography and follow-up","volume":"25","author":"Holmberg","year":"1993","journal-title":"Scand J Infect Dis"},{"key":"2026030321360974500_bib213","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2214\/AJR.13.10888","article-title":"Outcome of recommendations for radiographic follow-up of pneumonia on outpatient chest radiography","volume":"202","author":"Little","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"2026030321360974500_bib214","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1001\/archinternmed.2011.155","article-title":"Incidence, correlates, and chest radiographic yield of new lung cancer diagnosis in 3398 patients with pneumonia","volume":"171","author":"Tang","year":"2011","journal-title":"Arch Intern Med"},{"key":"2026030321360974500_bib215","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.amjmed.2009.08.009","article-title":"Diagnosis of pulmonary malignancy after hospitalization for pneumonia","volume":"123","author":"Mortensen","year":"2010","journal-title":"Am J Med"},{"key":"2026030321360974500_bib216","doi-asserted-by":"crossref","first-page":"330","DOI":"10.7326\/M13-2771","article-title":"Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement","volume":"160","author":"Moyer","year":"2014","journal-title":"Ann Intern Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/7\/e45\/67170385\/ajrccm_200_7_e45.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/200\/7\/e45\/67170385\/ajrccm_200_7_e45.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T02:36:33Z","timestamp":1772591793000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/200\/7\/e45\/8496962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,1]]},"references-count":216,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,10,1]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.1164\/rccm.201908-1581st","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736686989.793566303","asserted-by":"object"}]},"ISSN":["1073-449X","1535-4970"],"issn-type":[{"value":"1073-449X","type":"print"},{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2019,10,1]]}}}